EHMT2 and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, these results suggest that inhibition of EHMT1 and EHMT2 with BIX01294 sensitizes CML cells, and to a lesser extent on Jurkat, HeLa or HaCat cells to interferon treatment.